RESEARCH TRIANGLE PARK, N.C. – June 9, 2011 – Quintiles today announced the appointment of Dr. Cynthia L. Verst as Global Head of Late Phase Operations. In this role, Verst leads Quintiles’ dedicated business that bridges the gap between peri-approval and commercialization of marketed therapies.
“Dr. Verst brings a dynamic leadership style and record of success in establishing and growing Late Phase operations,” said John Ratliff, Quintiles’ President and Chief Operating Officer. “Biopharma companies have traditionally designed studies with a focus on meeting regulatory requirements. Today, as biopharma adapts to the changing healthcare landscape we call the New Health, stakeholders demand real-world evidence. Our customers need to take a more proactive approach to collecting this evidence, and we are well positioned to help them demonstrate product value using robust data from real-world settings.”
Quintiles’ late phase offerings include comprehensive, efficient resources to meet both safety and efficacy requirements. Solutions incorporate a combination of scientific rationale and operational models, direct access to patients, tailored data management, dedicated statistical analysis teams, and integration among clinical, consulting and commercial capabilities.
“The post-marketing environment is evolving rapidly, and Quintiles is uniquely positioned to ally with biopharma in late phase research,” Verst said. “Our breadth of expertise across clinical development and commercialization allows us to respond to increasing requirements for long-term safety data, tightening reimbursement criteria and strong competition to win the attention of prescribers and patients.” Verst has 17 years of biopharma experience and a proven track record of late phase operational leadership and innovation. Most recently, she was Senior Vice President, Global Late Phase Research, for Ingenix, where she and her team successfully established a new global Late Phase Research Business Unit. Previously, Verst led Kendle’s global Late Phase Business Unit. She began her career in biopharma at Procter & Gamble Pharmaceuticals as Section Head in its North American Medical and Technical Affairs group, successfully leading the Phase IIIB/IV research requirements of marketed products.
Verst has been directly involved and/or provided executive level oversight to hundreds of Phase IIIB, IV, registries, comparative effectiveness, and Health Economic & Outcomes Research (HEOR) programs, entailing more than one million patients and more than 150,000 investigators in more than 40 countries.
A native of Kentucky, Verst holds a Pharm.D. and B.S. in Pharmacy from the University of Cincinnati, an M.S. in Structural and Cellular Biology from the University of Illinois, and a B.S. in Biology and Chemistry from Northern Kentucky University.
Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries around the globe works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.